GREENER Fuels Act Would Undermine Investment in Advanced Biofuels, BIO Says

Mar 8 2018
BIO voiced its opposition to the GREENER Fuels Act, introduced by Sen. Tom Udall (D-NM) and Rep. Peter Welch (D-VT), because it would revise the Renewable Fuel Standard (RFS) in way that will chill investment in advanced biofuel.

BIO Applauds Introduction of the Ensuring the Value of the 340B Program Act of 2018

Mar 1 2018
Washington, DC (March 1, 2018) – BIO President and CEO Jim Greenwood issued the following statement today regarding the introduction by Senator Charles Grassley of S. 2453, the Ensuring the Value of the 340B Program Act of 2018:

BIO Selects Des Moines as Venue for the 2019 BIO World Congress on Industrial Biotechnology

Feb 26 2018
The Biotechnology Innovation Organization (BIO) today announced the selection of Des Moines, Iowa, as the location for the 2019 BIO World Congress on Industrial Biotechnology. The event will be held July 8-11, 2019 and it will host industry executives, investors, policy makers and academics from around the world and will feature the BIO One-on-One Partnering™ system.

BIO Statement on President’s Proposed 2019 Budget

Feb 13 2018
Washington, D.C. (February 13, 2018) — Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood issued the following statement in response to President Trump’s FY 2019 budget proposal.

BIO Expresses Strong Support for TRID Improvement Act

Feb 12 2018
Legislation provides critical regulatory relief to small, pre-revenue emerging companies Washington, D.C. (February 12, 2018)— The Biotechnology Innovation Organization (BIO) announced its strong support today for H.R. 3978, the TRID Improvement Act. The bill includes a provision known as the Fostering Innovation Act, which offers much needed regulatory relief to small biotechnology firms. 

BIO Releases Report on State of Innovation for Pain and Addiction Therapeutics

Feb 12 2018
Report highlights the need to stimulate innovation to battle the opioid epidemic Washington, DC (February 12, 2018) – Today, the Biotechnology Innovation Organization (BIO) released a new report, The State of Innovation in Highly Prevalent Chronic Diseases: Pain and Addiction Therapeutics. While many promising treatment approaches are in development, lower investment and pipeline breadth in pain and addiction relative to other disease areas with high societal health burdens demonstrates the need for incentivizing more research and clinical development in these areas.

BIO Applauds Introduction of the Vaccine Access Improvement Act

Feb 9 2018
Washington, DC (February 9, 2018) – – The Biotechnology Innovation Organization (BIO) applauds Reps. Mike Kelly (R-PA) and Brian Higgins (D-NY) for introducing H.R. 4993, the Vaccine Access Improvement Act, which would promote timely access to new first-in-class childhood and maternal vaccines. The legislation would update the tax code to ensure new first-in-class vaccines are promptly covered under the National Vaccine Injury Compensation Program (VICP).  

South Dakota Governor Daugaard Signs Bill Facilitating Patient Access to Interchangeable Biologic Medicines

Feb 9 2018

Washington, D.C. (February 09, 2018) – The Biotechnology Innovation Organization (BIO) and the South Dakota Biotech Association...

BIO Statement on Medicare Part D Changes in Budget Deal

Feb 8 2018
Washington, DC (February 8, 2018) – BIO President and CEO Jim Greenwood issued the following statement today regarding proposed changes to the Medicare Part D program in the announced budget deal.

BIO Statement on U.S. Falling to 12th Ranking of International Patent System Strength

Feb 8 2018
The steady decline of America as an innovation-supporting economy is due to an unbalanced patent challenge system.